Summary
The Trump administration has announced two new Medicare pilot programs, “Globe” and “Guard”, that aim to lower drug prices by tying rebates to prices paid in comparable countries. Tanabe Pharma has sold global rights to its top-selling drug, Radicava, to Shionogi for $2.5 billion. AstraZeneca’s experimental cancer drug, ceralasertib, failed a Phase 3 trial. CRISPR Therapeutics reported positive early data for its cell therapy, zugo-cel, in inflammatory diseases and cancer. Neurocrine Biosciences’ late-stage study for valbenazine in cerebral palsy failed to meet its goals. The FDA has expanded the use of Boehringer Ingelheim’s Jascayd for progressive pulmonary fibrosis.
Access impact
The proposed Medicare pilot programs, if advanced, could save $27 billion over five years by forcing drug companies to offer rebates that cover the difference in prices paid in the U.S. and comparable countries. Tanabe Pharma’s sale of Radicava’s global rights to Shionogi will allow the latter to sell the ALS drug in more countries, potentially increasing access for patients. The failure of AstraZeneca’s ceralasertib in a Phase 3 trial is a setback for patients with non-small cell lung tumors, as there are few treatment options available. However, the positive data for CRISPR Therapeutics’ zugo-cel provides hope for patients with relapsed or refractory large B-cell lymphomas and certain autoimmune conditions. The failure of Neurocrine Biosciences’ valbenazine in a late-stage study for cerebral palsy is disappointing for patients as there are currently no approved treatments for this condition. The FDA’s expansion of Boehringer Ingelheim’s Jascayd for progressive pulmonary fibrosis provides another treatment option for patients with this condition.
Top-3 domain lens
Clinical Effectiveness
AstraZeneca’s ceralasertib failed a Phase 3 trial in people with non-small cell lung tumors, showing little clinical effectiveness in this patient population.
Safety and Tolerability
Neurocrine Biosciences’ late-stage study for valbenazine in cerebral palsy failed to meet its goals, indicating potential safety and tolerability concerns with this treatment.
Cost-Effectiveness
The Trump administration’s proposed Medicare pilot programs, if advanced, could save $27 billion over five years by tying drug prices to those paid in comparable countries, potentially increasing cost-effectiveness for patients and payers.
Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #ClinicalEffectiveness #Safety #CostEffectiveness #Company #Drug #RegulatoryAgency
CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source
source: https://www.biopharmadive.com/news/trump-medicare-prices-shionogi-crispr-astrazeneca-neurocrine/808467/